SALT LAKE CITY - SINTX Technologies raises $3.8 million through warrant exercise

SALT LAKE CITY - SINTX Technologies, Inc. (NASDAQ:SINT), a developer of advanced ceramics for biomedical applications with a current market capitalization of $15.2 million, announced Monday it has entered into definitive agreements for the immediate exercise of certain outstanding warrants to raise approximately $3.8 million in gross proceeds. According to InvestingPro data, the company has been quickly burning through cash, making this capital raise crucial for its operations.

The transaction involves the exercise of warrants to purchase 1,099,431 shares of common stock at $3.32 per share. These warrants were originally issued in February 2025. In exchange for the immediate cash exercise, SINTX will issue new unregistered warrants to purchase up to 1,649,147 shares of common stock at an exercise price of $4.79 per share. While the company maintains a healthy current ratio of 2.57, indicating strong short-term liquidity, InvestingPro analysis reveals several additional key metrics about the company’s financial health.

The new warrants will be exercisable immediately upon issuance and will expire five and a half years after issuance. Holders of the original warrants will pay an additional $0.125 per new warrant, contributing approximately $206,143 to the total proceeds.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering, which is expected to close on or about September 9, 2025, subject to customary closing conditions.

SINTX intends to use the net proceeds for working capital purposes, according to the press release statement.

The company specializes in silicon nitride (Si₃N₄) technology for biomedical applications. The shares issuable upon exercise of the original warrants are registered under an effective registration statement, while the new warrants were offered through a private placement under applicable exemptions from registration requirements.

SINTX has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of shares issuable upon exercise of the new warrants.

In other recent news, SINTX Technologies, Inc. has secured a patent for its antipathogenic fibrous materials, which utilize silicon nitride to neutralize pathogens on contact. This patent extends to various applications, including medical devices and healthcare infrastructure. Additionally, SINTX announced findings from a peer-reviewed study conducted with Virginia Tech, demonstrating the antiviral efficacy of its silicon nitride material against virus strains such as SARS-CoV-2 and MERS-CoV. The study highlighted a significant reduction in infectious titers, achieving up to 99.97% reduction within 10 minutes of contact.

Moreover, SINTX has completed the acquisition of SiNAPTIC Surgical, LLC, enhancing its portfolio with FDA-cleared orthopedic and spine technologies. This acquisition includes interbody spinal implants and foot and ankle fusion wedges, with a new 510(k) premarket notification submitted recently. The company also finalized an agreement to acquire surgical business assets from SiNAPTIC Holdings, LLC, aimed at expanding its market in foot and ankle implant systems. These strategic moves are supported by clinical development and mechanical testing, potentially accelerating SINTX’s commercial launch activities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.